Advanced search
Publication Cover
Journal of Medical Economics Volume 27, 2024 - Issue 1
Submit an article Journal homepage
232
Views
0
CrossRef citations to date
0
Altmetric
Nephrology

Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model

Lijoy Varghesea Boehringer Ingelheim Singapore Pte. Ltd, Singapore, SingaporeCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6036-424XView further author information
ORCID Icon,
Poh Wan Changb Boehringer Ingelheim (Malaysia) Sdn. Bhd, Kuala Lumpur, MalaysiaView further author information
,
Sorrakorn Juntarasiripasc Boehringer Ingelheim (Thai) Ltd., Bangkok, ThailandView further author information
,
Hien Phamd Boehringer Ingelheim Vietnam LLC, Ha Noi, VietnamView further author information
&
Anastasia Ustere Boehringer Ingelheim International GmbH, Ingelheim am Rhein, GermanyView further author information
Pages 836-848 | Received 11 Feb 2024, Accepted 13 Jun 2024, Published online: 01 Jul 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.